Respiratory Diagnostics Market Analysis & Forecast 2024-2030

Global Respiratory Diagnostics Market is expected to reach USD 13130.59 million by 2031 with CAGR of 7.8 % between 2025 and 2031

Overview

Respiratory diseases such as asthma, chronic obstructive pulmonary disease, and pneumonia require constant monitoring and check-ups to assess the patient's health condition to provide proper treatment and therapies. The rising prevalence of chronic diseases has placed a significant burden on healthcare systems across the world. According to WHO (World Health Organization), chronic obstructive pulmonary disease is the third leading cause of death worldwide. Around 3 million people die, and 65 million people suffer from moderate to severe chronic obstructive pulmonary disease. Almost 334 million people suffer from asthma which is the most common chronic disease affecting 14% of children globally.  

Respiratory diagnostics offers diverse tests and assays to assess the health condition and decide the best treatment options. Improving healthcare infrastructure in developing countries, and rising adoption of cutting-edge technologies to diagnose respiratory disease is accelerating the growth of the Global Respiratory Diagnostics Market. However, high cost is hampering the growth of the market. Growing technological advancements in respiratory diagnostics will offer several lucrative growth opportunities for the growth of the market in the forecast period.  

Product types & Competitive analysis

Based on product & service types segment Global Respiratory Diagnostics Market is segmented into instruments and devices, assays and reagents, and services and software. The instruments and devices segment led the Global Respiratory Diagnostics Market accounting for the largest revenue market share in 2024. Diagnostic is essential in almost all areas of respiratory care practice, rising tests and assays frequency in laboratories from hospitals and other medical facilities has been a major driving factor for the growth of the instruments and devices segment. Assays and reagents were the fastest-growing segments in 2024 and are expected to show rapid growth in the forecast period 2024-2030.  

The competitive analysis included in the research study helps users understand key players' market positioning and marketing strategies. Several companies in the market are launching new diagnostic tests and assays to detect a wide range of respiratory diseases. For instance, in August 2020 Novacyt a clinical diagnostics company launched a test to distinguish the Covid-19 virus and other common respiratory diseases. The Winterplex test is PCR PCR-based test that detects the presence of the disease by amplifying its genetic material to a point where it can be spotted by researchers. Moreover, in February 2020 Bio-Rad Laboratories one of the leaders of life science research and clinical diagnostic products launched EDX respiratory panel control for use with molecular-based clinical assays.  

The newly launched product is the first multi-analyte control to test 22 analytes in a single vial, which can save laboratories considerable time and space on their instruments. EDX RP Positive Run Control is lab test control, prepared to be utilized during respiratory assays to monitor the result of that given assay. In addition to product development companies are collaborating with key players in the market to offer new products to the market. In November 2020, SpeeDx a molecular diagnostic solutions company partnered with Nepean Hospital to commercialize a host gene expression biomarker test for respiratory viral illness.  

Under the terms of the partnership, the company will work with the scientists to produce an essay that makes use of the IFI27 biomarker to detect severe respiratory disease in patients. The company has revealed that the test is based on In Signia technology for gene expression measurement and will run on standard lab equipment. 

Application & Regional analysis

Based on applications the market is divided into Hospital/clinical laboratories, Home Care, and Research laboratories. In terms of revenue generation, the hospital/clinical laboratories segment dominated the applications segment in 2024. Most of diagnostic tests are performed at hospital/clinical laboratories due to the presence of advanced equipment and professional physicians. The rising frequency of tests, the surge in the number of private laboratories, growing demand for lab equipment are driving the growth of the segment.  

The regional outlook of the research study is based on an analysis of the market in North America, Europe, Asia Pacific, the Middle East, South America, Africa & Rest of the World. North America led the Global Respiratory Diagnostics Market in 2023. The growth in the region was primarily driven by a significant increase in the number of tests and a rise in the prevalence of chronic respiratory diseases. The U.S. accounted for the largest revenue share in the year 2024 followed by Canada, according to CDC America (Centers for Disease Control and Prevention), around 9 million adults were diagnosed with chronic bronchitis in the year 2024 which is 3.6% of the U.S. population.  

In 2018 19.2 million adults were suffering from asthma in the U.S. Europe was second in terms of revenue generation in the year 2024 followed by the Asia Pacific. Rising respiratory diseases like asthma, chronic obstructive pulmonary disease (COPD), the presence of advanced healthcare facilities, and chronic diseases that require testing to diagnose and to avail proper medical treatment are some of the major factors driving the growth of the European market.  

Asia Pacific was the fastest-growing region growing at a significant pace and is projected to grow at the highest CAGR in the forecast period 2025-2031. The growth in the region was accounted for by the developing medical infrastructure, rising geriatric population, and adoption of digital tools and equipment in blood testing laboratories. In addition to this growing awareness regarding chronic respiratory disease diagnosis and the presence of a significantly large patient pool is driving the growth of the respiratory diagnostics market in the Asia Pacific.  

Respiratory Diagnostics Market : Product Types

• Instruments and devices
• Assays and reagents
• Services and software

Respiratory Diagnostics Market : Application

• Hospital/clinical laboratories
• Home Care
• Research laboratories

Respiratory Diagnostics Market : Competitive Analysis

The report includes accurate analysis of key players with Market Value, Company profile, and SWOT analysis. The Study consists of the following key players in the Respiratory Diagnostics Market :

• Medtronic
• Novartis AG
• Abbott
• Bayer AG
• Johnson & Johnson
• Dräger
• General Electric
• Masimo

Geographical analysis of Respiratory Diagnostics Market :

• North America
  • U.S.A
  • Canada
• Europe
  • France
  • Germany
  • Spain
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South East Asia
• Latin America
  • Brazil
• Middle East and Africa

Global Respiratory Diagnostics Market Report delivers a comprehensive analysis of the following parameters:

• Market Forecast for 2024-2030
• Market growth drivers
• Challenges and Opportunities
• Emerging and Current market trends
• Market player Capacity, Production, Revenue (Value)
• Supply (Production), Consumption, Export, Import analysis
• End user/application Analysis

---

Frequently Asked Questions (FAQ)